Zurich Cantonal Bank’s Amylyx Pharmaceuticals AMLX Stock Holding History

Zurich Cantonal Bank’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$305K	Sell	16,956 -23,834	-58%	-$369K	﹤0.01%	2176
2026 Q1	$567K	Buy	+40,790	New	+$574K	﹤0.01%	1772
2025 Q4	–	Sell	-1,906	Closed	-$25.9K	–	2588
2025 Q3	$25.9K	Sell	1,906 -917	-32%	-$8.63K	﹤0.01%	2473
2025 Q2	$18.1K	Sell	2,823 -329	-10%	-$1.6K	﹤0.01%	2491
2025 Q1	$11.2K	Buy	+3,152	New	+$11.2K	﹤0.01%	2586
2024 Q2	–	Sell	-10,022	Closed	-$28.5K	–	2645
2024 Q1	$28.5K	Sell	10,022 -367	-4%	-$4.8K	﹤0.01%	2607
2023 Q4	$153K	Buy	10,389 +4,255	+69%	+$65.2K	﹤0.01%	2235
2023 Q3	$112K	Buy	6,134 +859	+16%	+$18.2K	﹤0.01%	2305
2023 Q2	$114K	Buy	5,275 +4,588	+668%	+$124K	﹤0.01%	2284
2023 Q1	$20.2K	Buy	+687	New	+$23.9K	﹤0.01%	2752

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Jupiter Topco New York $245B AUM

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Zurich Cantonal Bank's AMLX Position: Q2 2026 in Review

Zurich Cantonal Bank reduced its Amylyx Pharmaceuticals (AMLX) stake by 58% in Q2 2026, selling an estimated $369K and leaving 16,956 shares worth $305K. The position accounts for ﹤0.01% of the portfolio, ranked #2176.

Zurich Cantonal Bank first reported a position in AMLX in Q1 2023 and has held it in 10 quarters since. The position peaked at $567K in Q1 2026. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

Zurich Cantonal Bank held 16,956 shares of Amylyx Pharmaceuticals worth $305K as of Q2 2026.
Zurich Cantonal Bank sold 23,834 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $369K.
Amylyx Pharmaceuticals made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #2176 holding.
Zurich Cantonal Bank first reported a position in Amylyx Pharmaceuticals in Q1 2023 and has held it in 10 quarters since.
Zurich Cantonal Bank's Amylyx Pharmaceuticals position peaked at $567K in Q1 2026.
206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.